Article Figures & Data
Figures
- Figure 1
The 5-year overall survival (OS) for pT1 gastric cancer (GC) patients. (A) Kaplan-Meier curves showing the 5-year OS of pT1N0, pT1N1, pT1N2, and pT1N3 GC patients. (B) Kaplan-Meier curves showing the 5-year OS of pT1N1 GC patients in the ACT and OBS groups. (C) Kaplan-Meier curves showing the 5-year OS of pT1N2 GC patients receiving S-1 and patients receiving Xelox. (D) Kaplan-Meier curves showing the 5-year OS of pT1N3 GC patients receiving S-1 and patients receiving Xelox. ACT, adjuvant chemotherapy; OBS, observation.
- Figure 2
The 5-year disease-specific survival (DSS) for pT1 gastric cancer (GC) patients. (A) Kaplan-Meier curves showing the 5-year DSS of pT1N0, pT1N1, pT1N2, and pT1N3 GC patients. (B) Kaplan-Meier curves showing the 5-year DSS of pT1N1 GC patients in the ACT and OBS groups. (C) Kaplan-Meier curves showing the 5-year DSS of pT1N2 GC patients receiving S-1 and patients receiving Xelox. (D) Kaplan-Meier curves showing the 5-year DSS of pT1N3 GC patients receiving S-1 and patients receiving Xelox. ACT, adjuvant chemotherapy; OBS, observation.
Tables
Variables Total (n = 1,050) LNM (−) (n = 899) LNM (+) (n = 151) P Age (years) 60 (52,67) 60 (52,67) 58 (50,67) 0.262 < 60 512 (48.8%) 432 (48.1%) 80 (53.0%) ≥ 60 538 (51.2%) 467 (51.9%) 71 (47.0%) Gender 0.015* Male 696 (66.3%) 609 (67.7%) 87 (57.6%) Female 354 (33.7%) 290 (32.3%) 64 (42.4%) Tumor size (cm) 2.0 (1.2,2.5) 2.0 (1.0,2.5) 2.0 (1.5,3.0) 0.002* ≤ 2 698 (66.5%) 614 (68.3%) 84 (55.6%) > 2 352 (33.5%) 285 (31.7%) 67 (44.4%) Tumor location 0.998 Upper 70 (6.7%) 60 (6.7%) 10 (6.6%) Middle 322 (30.7%) 276 (30.7%) 46 (30.5%) Lower 658 (62.7%) 563 (62.6%) 95 (62.9%) Gross type < 0.001* Ulcerated 340 (32.4%) 264 (29.4%) 76 (50.3%) Non-ulcerated 710 (67.6%) 635 (70.6%) 75 (49.7%) Degree of differentiation < 0.001* Differentiated 382 (36.4%) 356 (39.6%) 26 (17.2%) Undifferentiated 668 (63.6%) 543 (60.4%) 125 (82.8%) Histopathology < 0.001* Tub 381 (36.3%) 355 (39.5%) 26 (17.2%) Por 490 (46.7%) 389 (43.3%) 101 (66.9%) Sig 160 (15.2%) 140 (15.6%) 20 (13.2%) Muc 18 (1.7%) 14 (1.6%) 4 (2.6%) Pap 1 (0.1%) 1 (0.1%) 0 Examined lymph node 21 (17,29) 21 (17,28) 23 (18,32) 0.017* Her-2 status 0.268 Negative 919 (87.5%) 791 (88.0%) 128 (84.8%) Positive 131 (12.5%) 108 (12.0%) 23 (15.2%) Depth of tumor invasion < 0.001* T1a 512 (48.8%) 485 (53.9%) 27 (17.9%) T1b 538 (51.2%) 414 (46.1%) 124 (82.1%) Lymphovascular invasion 84 (8.0%) 53 (5.9%) 31 (20.5%) < 0.001* Perineural invasion 12 (1.1%) 6 (0.7%) 6 (4.0%) < 0.001* Treatments after surgery < 0.001* Observation 945 (90.0%) 899 (100%) 46 (30.5%) S-1 60 (5.7%) 0 60 (39.7%) Xelox 45 (4.3%) 0 45 (29.8%) *P < 0.05 was considered statistically significant. LNM, lymph node metastasis; Tub, tubular adenocarcinoma; Por, poorly differentiated adenocarcinoma; Sig, signet-ring cell carcinoma; Muc, mucinous adenocarcinoma; Pap, papillary adenocarcinoma; T1a, mucosal invasion; T1b, submucosal invasion.
- Table 2
Multivariate logistic regression analyses of lymph node metastases of early gastric cancer patients
Variables Multivariate analysis P Odds ratio 95% CI Tumor size > 2 cm 0.022 1.547 1.065–2.247 Ulceration 0.014 1.605 1.101–2.341 Undifferentiated < 0.001 2.834 1.791–4.483 Submucosal invasion < 0.001 3.941 2.486–6.249 Lymphovascular invasion 0.003 2.173 1.302–3.626 - Table 3
Univariate and multivariate analyses for the prognoses of early gastric cancer patients
Variables 5-year OS rate Univariate Multivariate P HR 95% CI P Age (years) 0.067 < 60 97.50% ≥ 60 95.40% Gender 0.678 Male 96.60% Female 96.00% Tumor size (cm) 0.251 ≤ 2 96.80% > 2 95.50% Tumor location 0.68 Upper 97.10% Middle 95.70% Lower 96.70% Gross type 0.329 Ulcerated 95.60% Non-ulcerated 96.80% Degree of differentiation 0.098 Differentiated 97.60% Undifferentiated 95.70% Histopathology 0.198 Tub 97.60% Por 94.90% Sig 97.50% Muc 100% Pap 100% Examined lymph node 0.967 Her-2 status < 0.001* Negative 97.20% Positive 90.80% 3.082 1.512–6.281 0.002* Depth of tumor invasion < 0.001* T1a 98.60% T1b 94.20% 2.026 0.832–4.935 0.12 LNM status < 0.001* Negative 98.30% Positive 84.80% 6.781 3.347–13.742 < 0.001* Lymphovascular invasion < 0.001* Negative 97.10% Positive 88.10% 1.359 0.605–3.054 0.458 Perineural invasion < 0.001* Negative 96.60% Positive 75.00% 4.035 1.122–14.506 0.033* *P < 0.05 was considered statistically significant. Tub, tubular adenocarcinoma; Por, poorly differentiated adenocarcinoma; Sig, signet-ring cell carcinoma; Muc, mucinous adenocarcinoma; Pap, papillary adenocarcinoma; T1a, mucosal invasion; T1b, submucosal invasion; OS, overall survival; HR, hazard ratio; CI, confidence interval.
Variables (n, %) pT1N1 (n = 109) pT1N2 (n = 23) pT1N3 (n = 19) OBS (n = 46) ACT (n = 63) P S-1 (n = 11) Xelox (n = 12) P S-1 (n = 7) Xelox (n = 12) P Age (years) 0.639 0.51 0.044* < 60 24 (52.2) 30 (47.6) 7 (63.6) 6 (50.0) 7 (100) 6 (50.0) ≥ 60 22 (47.8) 33 (52.4) 4 (36.4) 6 (50.0) 0 6 (50.0) Gender 0.735 0.214 0.656 Male 27 (58.7) 39 (61.9) 5 (45.5) 9 (75.0) 2 (28.6) 5 (41.7) Female 19 (41.3) 24 (38.1) 6 (54.5) 3 (25.0) 5 (71.4) 7 (58.3) Tumor size (cm) 0.92 0.059 0.96 ≤ 2 26 (56.5) 35 (55.6) 8 (72.7) 4 (33.3) 4 (57.1) 7 (58.3) > 2 20 (43.5) 28 (44.4) 3 (27.3) 8 (66.7) 3 (42.9) 5 (41.7) Tumor location 0.334 0.775 0.731 Upper 2 (4.3) 4 (6.3) 2 (18.2) 1 (8.3) 0 1 (8.3) Middle 10 (21.7) 21 (33.3) 3 (27.3) 4 (33.3) 3 (42.9) 5 (41.7) Lower 34 (73.9) 38 (60.3) 6 (54.5) 7 (58.3) 4 (57.1) 6 (50.0) Gross type 0.177 0.4 0.35 Ulcerated 21 (45.7) 37 (58.7) 3 (27.3) 6 (50.0) 2 (28.6) 7 (58.3) Non-ulcerated 25 (54.3) 26 (41.3) 8 (72.7) 6 (50.0) 5 (71.4) 5 (41.7) Differentiation 0.302 0.155 0.433 Differentiated 6 (13.0) 13 (20.6) 1 (9.1) 5 (41.7) 0 1 (8.3) Undifferentiated 40 (87.0) 50 (79.4) 10 (90.9) 7 (58.3) 7 (100) 11 (91.7) Histopathology 0.63 0.116 0.432 Tub 6 (13.0) 13 (20.6) 1 (9.1) 5 (41.7) 0 1 (8.3) Por 32 (69.6) 42 (66.7) 8 (72.7) 6 (50.0) 6 (85.7) 7 (58.3) Sig 6 (13.0) 7 (11.1) 2 (18.2) 0 1 (14.3) 4 (33.3) Muc 2 (4.3) 1 (1.6) 0 1 (8.3) 0 0 Examined lymph node 21 (17,29) 22 (18,34) 0.232 27 (19,31) 28 (21,35) 0.487 30 (19,34) 30 (17,43) 0.902 Her-2 status 0.061 0.901 0.683 Negative 43 (93.5) 51 (81.0) 8 (72.7) 9 (75.0) 6 (85.7) 11 (91.7) Positive 3 (6.5) 12 (19.0) 3 (27.3) 3 (25.0) 1 (14.3) 1 (8.3) Depth of invasion 0.889 0.052 0.433 T1a 10 (21.7) 13 (20.6) 3 (27.3) 0 0 1 (8.3) T1b 36 (78.3) 50 (79.4) 8 (72.7) 12 (100) 7 (100) 11 (91.7) Lymphovascular invasion 3 (6.5) 11 (17.5) 0.092 2 (18.2) 5 (41.7) 0.371 5 (71.4) 5 (41.7) 0.35 Perineural invasion 1 (2.2) 1 (1.6) 0.822 0 0 1 2 (28.6) 2 (16.7) 0.603 *P < 0.05 was considered statistically significant. Tub, tubular adenocarcinoma; Por, poorly differentiated adenocarcinoma; Sig, signet-ring cell carcinoma; Muc, mucinous adenocarcinoma; Pap, papillary adenocarcinoma; T1a, mucosal invasion; T1b, submucosal invasion; OBS, observation; ACT, adjuvant chemotherapy.
- Table 5
Univariate and multivariate analyses for the prognoses of pT1N1 gastric cancer patients
Variables 5-year OS rate Univariate Multivariate P HR 95% CI P Age (years) 0.005* < 60 98.10% ≥ 60 81.80% 6.491 0.805–52.325 0.079 Gender 0.031* Male 84.80% 5.103 0.648–40.176 0.122 Female 97.70% Tumor size (cm) 0.168 ≤ 2 93.40% > 2 85.40% Tumor location 0.027* Upper 100% Middle 77.40% 3.761 1.086–13.033 0.037* Lower 94.40% Gross type 0.906 Ulcerated 89.70% Non-ulcerated 90.20% Degree of differentiation 0.358 Differentiated 84.20% Undifferentiated 91.10% Histopathology 0.486 Tub 84.20% Por 89.20% Sig 100% Muc 100% Examined lymph node 0.644 Her-2 status 0.015* Negative 92.60% Positive 73.30% 4.517 1.303–15.657 0.017* Depth of tumor invasion 0.308 T1a 95.70% T1b 88.40% Lymphovascular invasion 0.682 Negative 89.50% Positive 92.90% Perineural invasion 0.642 Negative 89.70% Positive 100% Treatment after surgery 0.782 OBS 89.10% ACT 90.50% *P < 0.05 was considered statistically significant. Tub, tubular adenocarcinoma; Por, poorly differentiated adenocarcinoma; Sig, signet-ring cell carcinoma; Muc, mucinous adenocarcinoma; T1a, mucosal invasion; T1b, submucosal invasion; OS, overall survival; HR, hazard ratio; CI, confidence interval; OBS, observation; ACT, adjuvant chemotherapy.
Variables 5-year OS rate P Age (years) 0.427 < 60 92.30% ≥ 60 80.00% Gender 0.304 Male 92.90% Female 77.80% Tumor size (cm) 0.459 ≤ 2 91.70% > 2 81.80% Tumor location 0.555 Upper 66.70% Middle 85.70% Lower 92.30% Gross type 0.149 Ulcerated 100% Non-ulcerated 78.60% Degree of differentiation 0.815 Differentiated 83.30% Undifferentiated 98.20% Histopathology 0.923 Tub 83.30% Por 85.70% Sig 100% Muc 100% Examined lymph node 0.936 Her-2 status 0.815 Negative 88.20% Positive 83.30% Depth of tumor invasion 0.491 T1a 100% T1b 85.00% Lymphovascular invasion 0.147 Negative 93.80% Positive 71.40% Treatment after surgery 0.528 S-1 81.80% Xelox 91.70% Tub, tubular adenocarcinoma; Por, poorly differentiated adenocarcinoma; Sig, signet-ring cell carcinoma; Muc, mucinous adenocarcinoma; T1a, mucosal invasion; T1b, submucosal invasion; OS, overall survival.
Variables 5-year OS rate P Age (years) 0.418 < 60 46.20% ≥ 60 66.70% Gender 0.603 Male 57.10% Female 50.00% Tumor size (cm) 0.514 ≤ 2 45.50% > 2 62.50% Tumor location 0.404 Upper 100% Middle 37.50% Lower 60.00% Gross type 0.578 Ulcerated 44.40% Non-ulcerated 60.00% Degree of differentiation 0.413 Differentiated 100% Undifferentiated 50.00% Histopathology 0.412 Tub 100% Por 53.80% Sig 40.00% Examined lymph node 0.604 Her-2 status 0.669 Negative 52.90% Positive 50.00% Depth of tumor invasion 0.413 T1a 100% T1b 50.00% N stage 0.837 N3a 53.30% N3b 50.00% Lymphovascular invasion 0.287 Negative 66.70% Positive 40.00% Perineural invasion 0.114 Negative 60.00% Positive 25.00% Treatment after surgery 0.009* S-1 14.30% Xelox 75.00% *P < 0.05 was considered statistically significant. Tub, tubular adenocarcinoma; Por, poorly differentiated adenocarcinoma; Sig, signet-ring cell carcinoma; T1a, mucosal invasion; T1b, submucosal invasion; OS, overall survival.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.